Combination Nanovaccine Demonstrates Synergistic Enhancement in Efficacy against Influenza

Kathleen Ross, Justin Adams, Hyelee Loyd, Shaheen Ahmed, Anthony R. Sambol, Scott Broderick, Krishna Rajan, Marian Kohut, Tatiana K Bronich, Michael J. Wannemuehler, Susan Carpenter, Surya Mallapragada, Balaji Narasimhan

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

H5N1 influenza virus has the potential to become a significant global health threat, and next generation vaccine technologies are needed. In this work, the combined efficacy of two nanoadjuvant platforms (polyanhydride nanoparticles and pentablock copolymer-based hydrogels) to induce protective immunity against H5N1 influenza virus was examined. Mice received two subcutaneous vaccinations (day 0 and 21) containing 10 μg of H5 hemagglutinin trimer alone or in combination with the nanovaccine platforms. Nanovaccine immunization induced high neutralizing antibody titers that were sustained through 70 days postimmunization. Finally, mice were intranasally challenged with A/H5N1 VNH5N1-PR8CDC-RG virus and monitored for 14 days. Animals receiving the combination nanovaccine had lower viral loads in the lung and weight loss after challenge in comparison to animals vaccinated with each platform alone. These data demonstrate the synergy between polyanhydride nanoparticles and pentablock copolymer-based hydrogels as adjuvants in the design of a more efficacious influenza vaccine.

Original languageEnglish (US)
Pages (from-to)368-374
Number of pages7
JournalACS Biomaterials Science and Engineering
Volume2
Issue number3
DOIs
StatePublished - Mar 14 2016

Fingerprint

Polyanhydrides
Viruses
Hydrogels
Vaccines
Animals
Copolymers
Nanoparticles
Immunization
Influenza Vaccines
Neutralizing Antibodies
Antibodies
Health

Keywords

  • H5 hemagglutinin
  • PDEAEM
  • combination nanovaccine
  • hydrogel
  • influenza
  • nanoparticle
  • polyanhydride

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering

Cite this

Combination Nanovaccine Demonstrates Synergistic Enhancement in Efficacy against Influenza. / Ross, Kathleen; Adams, Justin; Loyd, Hyelee; Ahmed, Shaheen; Sambol, Anthony R.; Broderick, Scott; Rajan, Krishna; Kohut, Marian; Bronich, Tatiana K; Wannemuehler, Michael J.; Carpenter, Susan; Mallapragada, Surya; Narasimhan, Balaji.

In: ACS Biomaterials Science and Engineering, Vol. 2, No. 3, 14.03.2016, p. 368-374.

Research output: Contribution to journalArticle

Ross, K, Adams, J, Loyd, H, Ahmed, S, Sambol, AR, Broderick, S, Rajan, K, Kohut, M, Bronich, TK, Wannemuehler, MJ, Carpenter, S, Mallapragada, S & Narasimhan, B 2016, 'Combination Nanovaccine Demonstrates Synergistic Enhancement in Efficacy against Influenza', ACS Biomaterials Science and Engineering, vol. 2, no. 3, pp. 368-374. https://doi.org/10.1021/acsbiomaterials.5b00477
Ross, Kathleen ; Adams, Justin ; Loyd, Hyelee ; Ahmed, Shaheen ; Sambol, Anthony R. ; Broderick, Scott ; Rajan, Krishna ; Kohut, Marian ; Bronich, Tatiana K ; Wannemuehler, Michael J. ; Carpenter, Susan ; Mallapragada, Surya ; Narasimhan, Balaji. / Combination Nanovaccine Demonstrates Synergistic Enhancement in Efficacy against Influenza. In: ACS Biomaterials Science and Engineering. 2016 ; Vol. 2, No. 3. pp. 368-374.
@article{c51deaae20ff48949a6e28d3a1106413,
title = "Combination Nanovaccine Demonstrates Synergistic Enhancement in Efficacy against Influenza",
abstract = "H5N1 influenza virus has the potential to become a significant global health threat, and next generation vaccine technologies are needed. In this work, the combined efficacy of two nanoadjuvant platforms (polyanhydride nanoparticles and pentablock copolymer-based hydrogels) to induce protective immunity against H5N1 influenza virus was examined. Mice received two subcutaneous vaccinations (day 0 and 21) containing 10 μg of H5 hemagglutinin trimer alone or in combination with the nanovaccine platforms. Nanovaccine immunization induced high neutralizing antibody titers that were sustained through 70 days postimmunization. Finally, mice were intranasally challenged with A/H5N1 VNH5N1-PR8CDC-RG virus and monitored for 14 days. Animals receiving the combination nanovaccine had lower viral loads in the lung and weight loss after challenge in comparison to animals vaccinated with each platform alone. These data demonstrate the synergy between polyanhydride nanoparticles and pentablock copolymer-based hydrogels as adjuvants in the design of a more efficacious influenza vaccine.",
keywords = "H5 hemagglutinin, PDEAEM, combination nanovaccine, hydrogel, influenza, nanoparticle, polyanhydride",
author = "Kathleen Ross and Justin Adams and Hyelee Loyd and Shaheen Ahmed and Sambol, {Anthony R.} and Scott Broderick and Krishna Rajan and Marian Kohut and Bronich, {Tatiana K} and Wannemuehler, {Michael J.} and Susan Carpenter and Surya Mallapragada and Balaji Narasimhan",
year = "2016",
month = "3",
day = "14",
doi = "10.1021/acsbiomaterials.5b00477",
language = "English (US)",
volume = "2",
pages = "368--374",
journal = "ACS Biomaterials Science and Engineering",
issn = "2373-9878",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Combination Nanovaccine Demonstrates Synergistic Enhancement in Efficacy against Influenza

AU - Ross, Kathleen

AU - Adams, Justin

AU - Loyd, Hyelee

AU - Ahmed, Shaheen

AU - Sambol, Anthony R.

AU - Broderick, Scott

AU - Rajan, Krishna

AU - Kohut, Marian

AU - Bronich, Tatiana K

AU - Wannemuehler, Michael J.

AU - Carpenter, Susan

AU - Mallapragada, Surya

AU - Narasimhan, Balaji

PY - 2016/3/14

Y1 - 2016/3/14

N2 - H5N1 influenza virus has the potential to become a significant global health threat, and next generation vaccine technologies are needed. In this work, the combined efficacy of two nanoadjuvant platforms (polyanhydride nanoparticles and pentablock copolymer-based hydrogels) to induce protective immunity against H5N1 influenza virus was examined. Mice received two subcutaneous vaccinations (day 0 and 21) containing 10 μg of H5 hemagglutinin trimer alone or in combination with the nanovaccine platforms. Nanovaccine immunization induced high neutralizing antibody titers that were sustained through 70 days postimmunization. Finally, mice were intranasally challenged with A/H5N1 VNH5N1-PR8CDC-RG virus and monitored for 14 days. Animals receiving the combination nanovaccine had lower viral loads in the lung and weight loss after challenge in comparison to animals vaccinated with each platform alone. These data demonstrate the synergy between polyanhydride nanoparticles and pentablock copolymer-based hydrogels as adjuvants in the design of a more efficacious influenza vaccine.

AB - H5N1 influenza virus has the potential to become a significant global health threat, and next generation vaccine technologies are needed. In this work, the combined efficacy of two nanoadjuvant platforms (polyanhydride nanoparticles and pentablock copolymer-based hydrogels) to induce protective immunity against H5N1 influenza virus was examined. Mice received two subcutaneous vaccinations (day 0 and 21) containing 10 μg of H5 hemagglutinin trimer alone or in combination with the nanovaccine platforms. Nanovaccine immunization induced high neutralizing antibody titers that were sustained through 70 days postimmunization. Finally, mice were intranasally challenged with A/H5N1 VNH5N1-PR8CDC-RG virus and monitored for 14 days. Animals receiving the combination nanovaccine had lower viral loads in the lung and weight loss after challenge in comparison to animals vaccinated with each platform alone. These data demonstrate the synergy between polyanhydride nanoparticles and pentablock copolymer-based hydrogels as adjuvants in the design of a more efficacious influenza vaccine.

KW - H5 hemagglutinin

KW - PDEAEM

KW - combination nanovaccine

KW - hydrogel

KW - influenza

KW - nanoparticle

KW - polyanhydride

UR - http://www.scopus.com/inward/record.url?scp=84969262418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969262418&partnerID=8YFLogxK

U2 - 10.1021/acsbiomaterials.5b00477

DO - 10.1021/acsbiomaterials.5b00477

M3 - Article

AN - SCOPUS:84969262418

VL - 2

SP - 368

EP - 374

JO - ACS Biomaterials Science and Engineering

JF - ACS Biomaterials Science and Engineering

SN - 2373-9878

IS - 3

ER -